European Union - English - EMA (European Medicines Agency)

viatris limited - pirfenidone - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - immunosuppressants - pirfenidone viatris is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).

European Union - English - EMA (European Medicines Agency)

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - drugs used in diabetes - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance.- in addition to other medicinal products for the treatment of type 2 diabetes.for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1.heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction.chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - atazanavir sulfate 170.85mg equivalent to atazanavir 150mg; atazanavir sulfate 170.85mg equivalent to atazanavir 150mg - capsule - 150 mg - active: atazanavir sulfate 170.85mg equivalent to atazanavir 150mg excipient: crospovidone gelatin   iron oxide red lactose monohydrate magnesium stearate patent blue v   purified water   tekprint black sw-9008 titanium dioxide   active: atazanavir sulfate 170.85mg equivalent to atazanavir 150mg excipient: brilliant blue fcf   crospovidone erythrosine gelatin iron oxide yellow lactose monohydrate magnesium stearate purified water   titanium dioxide   - atazanavir viatris is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents, in adult patients and in paediatric patients 6 to 18 years of age. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - atazanavir sulfate 227.8mg equivalent to atazanavir 200mg; atazanavir sulfate 227.8mg equivalent to atazanavir 200mg - capsule - 200 mg - active: atazanavir sulfate 227.8mg equivalent to atazanavir 200mg excipient: brilliant blue fcf   crospovidone erythrosine gelatin   lactose monohydrate magnesium stearate purified water   titanium dioxide   active: atazanavir sulfate 227.8mg equivalent to atazanavir 200mg excipient: crospovidone gelatin   indigo carmine iron oxide yellow lactose monohydrate magnesium stearate patent blue v purified water   tekprint black sw-9008 titanium dioxide   - atazanavir viatris is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents, in adult patients and in paediatric patients 6 to 18 years of age. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - atazanavir sulfate 341.7mg equivalent to atazanavir 300mg; atazanavir sulfate 341.7mg equivalent to atazanavir 300mg - capsule - 300 mg - active: atazanavir sulfate 341.7mg equivalent to atazanavir 300mg excipient: brilliant blue fcf crospovidone erythrosine gelatin   iron oxide red iron oxide yellow lactose monohydrate magnesium stearate purified water   titanium dioxide   active: atazanavir sulfate 341.7mg equivalent to atazanavir 300mg excipient: crospovidone gelatin   iron oxide red   iron oxide yellow lactose monohydrate magnesium stearate patent blue v purified water   tekprint black sw-9008 titanium dioxide   - atazanavir viatris is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents, in adult patients and in paediatric patients 6 to 18 years of age. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies.

Malta - English - Medicines Authority

viatris limited damastown industrial park, mulhuddart, dublin 15, dublin, ireland - film-coated tablet - quetiapine fumarate 25 mg - psycholeptics

Malta - English - Medicines Authority

viatris limited damastown industrial park, mulhuddart, dublin 15, dublin, ireland - film-coated tablet - quetiapine fumarate 100 mg - psycholeptics

Malta - English - Medicines Authority

viatris limited damastown industrial park, mulhuddart, dublin 15, dublin, ireland - film-coated tablet - quetiapine fumarate 200 mg - psycholeptics

Malta - English - Medicines Authority

viatris limited damastown industrial park, mulhuddart, dublin 15, dublin, ireland - film-coated tablet - quetiapine fumarate 300 mg - psycholeptics

European Union - English - EMA (European Medicines Agency)

viatris limited - clopidogrel besilate - peripheral vascular diseases; stroke; myocardial infarction - antithrombotic agents - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.adult patients suffering from acute coronary syndrome.non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa).st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event.prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke.for further information please refer to section 5.1.